Concepts (251)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Hepatocellular | 6 | 2021 | 145 | 1.940 |
Why?
|
| Liver Neoplasms | 6 | 2021 | 190 | 1.320 |
Why?
|
| Li-Fraumeni Syndrome | 3 | 2016 | 3 | 1.290 |
Why?
|
| Tumor Suppressor Protein p53 | 4 | 2019 | 213 | 0.890 |
Why?
|
| Hepatitis C, Chronic | 2 | 2020 | 39 | 0.840 |
Why?
|
| Bariatric Surgery | 1 | 2021 | 17 | 0.760 |
Why?
|
| Gastric Bypass | 1 | 2021 | 17 | 0.760 |
Why?
|
| Weight Loss | 1 | 2021 | 131 | 0.710 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 16 | 0.700 |
Why?
|
| Gene Silencing | 2 | 2019 | 151 | 0.700 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 807 | 0.680 |
Why?
|
| DNA Methylation | 2 | 2019 | 325 | 0.670 |
Why?
|
| Antiviral Agents | 1 | 2020 | 157 | 0.650 |
Why?
|
| Antihypertensive Agents | 1 | 2021 | 284 | 0.620 |
Why?
|
| Medication Adherence | 1 | 2020 | 179 | 0.620 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2016 | 98 | 0.580 |
Why?
|
| Hepacivirus | 3 | 2018 | 62 | 0.570 |
Why?
|
| Neoplastic Stem Cells | 1 | 2016 | 78 | 0.530 |
Why?
|
| Humans | 35 | 2023 | 37093 | 0.510 |
Why?
|
| Epigenesis, Genetic | 1 | 2016 | 219 | 0.480 |
Why?
|
| Hypertension | 1 | 2021 | 796 | 0.460 |
Why?
|
| Obesity | 2 | 2021 | 1067 | 0.450 |
Why?
|
| Disease Progression | 5 | 2023 | 601 | 0.440 |
Why?
|
| Caveolin 1 | 1 | 2012 | 29 | 0.430 |
Why?
|
| Translocation, Genetic | 2 | 2016 | 42 | 0.420 |
Why?
|
| Gastrointestinal Diseases | 2 | 2023 | 42 | 0.400 |
Why?
|
| Minority Groups | 1 | 2016 | 596 | 0.380 |
Why?
|
| Retrospective Studies | 6 | 2023 | 2026 | 0.370 |
Why?
|
| Colonic Polyps | 2 | 2020 | 67 | 0.330 |
Why?
|
| Female | 18 | 2023 | 20969 | 0.330 |
Why?
|
| Breast Neoplasms | 3 | 2016 | 1502 | 0.330 |
Why?
|
| Male | 16 | 2023 | 20025 | 0.330 |
Why?
|
| Cohort Studies | 3 | 2023 | 1492 | 0.320 |
Why?
|
| Janus Kinase 2 | 1 | 2008 | 32 | 0.310 |
Why?
|
| Mesoderm | 1 | 2008 | 70 | 0.310 |
Why?
|
| STAT5 Transcription Factor | 1 | 2008 | 46 | 0.310 |
Why?
|
| Liver Cirrhosis | 2 | 2018 | 52 | 0.300 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2006 | 7 | 0.280 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 15 | 0.280 |
Why?
|
| Genes, p53 | 1 | 2006 | 25 | 0.280 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2010 | 421 | 0.280 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2008 | 194 | 0.270 |
Why?
|
| Down-Regulation | 2 | 2012 | 435 | 0.260 |
Why?
|
| Adult | 10 | 2023 | 11712 | 0.260 |
Why?
|
| Colorectal Neoplasms | 2 | 2020 | 441 | 0.240 |
Why?
|
| Epithelial Cells | 1 | 2008 | 384 | 0.240 |
Why?
|
| Corneal Dystrophies, Hereditary | 2 | 2006 | 2 | 0.240 |
Why?
|
| Middle Aged | 11 | 2023 | 10129 | 0.230 |
Why?
|
| Liver Diseases | 1 | 2023 | 33 | 0.230 |
Why?
|
| Azetidines | 1 | 2013 | 7 | 0.230 |
Why?
|
| Fibroblasts | 3 | 2016 | 272 | 0.230 |
Why?
|
| Heptanoic Acids | 1 | 2013 | 12 | 0.230 |
Why?
|
| Microscopy, Confocal | 2 | 2006 | 218 | 0.220 |
Why?
|
| Pyrroles | 1 | 2013 | 55 | 0.220 |
Why?
|
| Blood Coagulation | 1 | 2023 | 23 | 0.220 |
Why?
|
| Cell Line, Tumor | 4 | 2016 | 2231 | 0.220 |
Why?
|
| Autoimmunity | 1 | 2023 | 53 | 0.220 |
Why?
|
| Karyotyping | 2 | 2016 | 47 | 0.210 |
Why?
|
| Chromatography, Liquid | 1 | 2013 | 142 | 0.210 |
Why?
|
| Hepatitis C | 2 | 2018 | 125 | 0.200 |
Why?
|
| Risk Factors | 5 | 2021 | 3562 | 0.200 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2013 | 182 | 0.200 |
Why?
|
| Aged | 7 | 2022 | 6741 | 0.190 |
Why?
|
| Head and Neck Neoplasms | 1 | 2001 | 78 | 0.190 |
Why?
|
| Chromatography, Thin Layer | 1 | 2010 | 37 | 0.190 |
Why?
|
| Signal Transduction | 2 | 2016 | 1908 | 0.180 |
Why?
|
| Liver Function Tests | 1 | 2020 | 18 | 0.180 |
Why?
|
| beta Catenin | 1 | 2020 | 48 | 0.180 |
Why?
|
| Interferons | 1 | 2020 | 34 | 0.180 |
Why?
|
| Uterine Diseases | 1 | 2019 | 5 | 0.180 |
Why?
|
| Polyps | 1 | 2019 | 9 | 0.180 |
Why?
|
| Caco-2 Cells | 1 | 2019 | 52 | 0.180 |
Why?
|
| Liver | 2 | 2019 | 479 | 0.180 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 178 | 0.180 |
Why?
|
| Hep G2 Cells | 1 | 2019 | 51 | 0.180 |
Why?
|
| Colitis, Ulcerative | 1 | 2020 | 54 | 0.170 |
Why?
|
| Crohn Disease | 1 | 2020 | 63 | 0.170 |
Why?
|
| Colitis | 1 | 2020 | 65 | 0.170 |
Why?
|
| Age Factors | 2 | 2020 | 1033 | 0.170 |
Why?
|
| Carrier Proteins | 1 | 2001 | 305 | 0.170 |
Why?
|
| Sex Factors | 2 | 2020 | 898 | 0.170 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 120 | 0.170 |
Why?
|
| Metabolome | 1 | 2019 | 53 | 0.170 |
Why?
|
| Alleles | 1 | 2020 | 321 | 0.170 |
Why?
|
| Indoles | 1 | 2010 | 158 | 0.170 |
Why?
|
| Inflammatory Bowel Diseases | 1 | 2020 | 92 | 0.160 |
Why?
|
| Metabolomics | 1 | 2019 | 81 | 0.160 |
Why?
|
| Biomedical Research | 1 | 2023 | 400 | 0.160 |
Why?
|
| Viral Load | 1 | 2020 | 312 | 0.160 |
Why?
|
| Poly(ADP-ribose) Polymerases | 3 | 2003 | 78 | 0.160 |
Why?
|
| Incidence | 1 | 2021 | 922 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 610 | 0.150 |
Why?
|
| Genotype | 1 | 2020 | 730 | 0.150 |
Why?
|
| Mutation | 2 | 2006 | 1095 | 0.150 |
Why?
|
| Galactose | 1 | 1996 | 8 | 0.140 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 626 | 0.140 |
Why?
|
| Treatment Outcome | 1 | 2021 | 1369 | 0.140 |
Why?
|
| 2-Pyridinylmethylsulfinylbenzimidazoles | 1 | 2006 | 3 | 0.140 |
Why?
|
| Omeprazole | 1 | 2006 | 6 | 0.140 |
Why?
|
| Fatty Liver | 1 | 2017 | 64 | 0.140 |
Why?
|
| Proton Pump Inhibitors | 1 | 2006 | 9 | 0.140 |
Why?
|
| Germ-Line Mutation | 1 | 2016 | 57 | 0.140 |
Why?
|
| Calcium-Binding Proteins | 1 | 2016 | 76 | 0.140 |
Why?
|
| Cell Proliferation | 2 | 2019 | 1198 | 0.140 |
Why?
|
| Body Mass Index | 1 | 2020 | 854 | 0.130 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2020 | 767 | 0.130 |
Why?
|
| DNA, Mitochondrial | 1 | 1996 | 175 | 0.130 |
Why?
|
| RNA, Messenger | 1 | 2020 | 1207 | 0.130 |
Why?
|
| Pyridines | 1 | 2016 | 116 | 0.130 |
Why?
|
| Prospective Studies | 3 | 2023 | 1378 | 0.130 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2016 | 190 | 0.130 |
Why?
|
| Cell Nucleus | 1 | 1996 | 366 | 0.120 |
Why?
|
| MicroRNAs | 1 | 2020 | 426 | 0.120 |
Why?
|
| Models, Biological | 1 | 2018 | 677 | 0.120 |
Why?
|
| RNA, Small Interfering | 1 | 2016 | 409 | 0.120 |
Why?
|
| Health Status Disparities | 1 | 2020 | 642 | 0.120 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 515 | 0.120 |
Why?
|
| Phenotype | 1 | 2016 | 689 | 0.120 |
Why?
|
| Cell Line | 4 | 2016 | 1354 | 0.120 |
Why?
|
| DNA | 1 | 1996 | 574 | 0.110 |
Why?
|
| Mitochondria | 1 | 1996 | 487 | 0.110 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2012 | 55 | 0.110 |
Why?
|
| Feedback, Physiological | 1 | 2012 | 31 | 0.110 |
Why?
|
| Gene Expression | 3 | 2012 | 674 | 0.110 |
Why?
|
| Benzothiazoles | 1 | 2012 | 21 | 0.100 |
Why?
|
| Benzofurans | 1 | 2012 | 21 | 0.100 |
Why?
|
| Benzimidazoles | 1 | 2012 | 36 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 59 | 0.100 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2012 | 306 | 0.100 |
Why?
|
| Prevalence | 3 | 2020 | 1455 | 0.100 |
Why?
|
| Cell Cycle | 1 | 2012 | 326 | 0.100 |
Why?
|
| Up-Regulation | 1 | 2012 | 513 | 0.090 |
Why?
|
| United States | 2 | 2017 | 4223 | 0.080 |
Why?
|
| Drug Stability | 2 | 2010 | 116 | 0.080 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 91 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2020 | 753 | 0.070 |
Why?
|
| Ophthalmoscopes | 1 | 2006 | 2 | 0.070 |
Why?
|
| Chromosome Banding | 1 | 2006 | 6 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2006 | 53 | 0.070 |
Why?
|
| Homozygote | 1 | 2006 | 77 | 0.070 |
Why?
|
| Heterozygote | 1 | 2006 | 93 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2017 | 2379 | 0.070 |
Why?
|
| Logistic Models | 2 | 2020 | 923 | 0.070 |
Why?
|
| Neuroblastoma | 1 | 2006 | 129 | 0.060 |
Why?
|
| DNA Fragmentation | 2 | 2002 | 92 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2008 | 587 | 0.060 |
Why?
|
| Vomiting | 1 | 2023 | 14 | 0.060 |
Why?
|
| Reproducibility of Results | 2 | 2013 | 935 | 0.060 |
Why?
|
| Tumor Cells, Cultured | 2 | 2002 | 502 | 0.060 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 2 | 2002 | 187 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2023 | 41 | 0.060 |
Why?
|
| Fatigue | 1 | 2023 | 83 | 0.050 |
Why?
|
| Etoposide | 1 | 2002 | 22 | 0.050 |
Why?
|
| Troponin | 1 | 2022 | 15 | 0.050 |
Why?
|
| Endodeoxyribonucleases | 1 | 2002 | 29 | 0.050 |
Why?
|
| Osteosarcoma | 1 | 2002 | 26 | 0.050 |
Why?
|
| Proteins | 2 | 2002 | 369 | 0.050 |
Why?
|
| Bone Neoplasms | 1 | 2002 | 45 | 0.050 |
Why?
|
| Ferritins | 1 | 2022 | 55 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2001 | 62 | 0.050 |
Why?
|
| Diarrhea | 1 | 2022 | 89 | 0.050 |
Why?
|
| Neoplasm Transplantation | 1 | 2001 | 122 | 0.050 |
Why?
|
| Blotting, Northern | 1 | 2001 | 150 | 0.050 |
Why?
|
| Apoptosis | 2 | 2016 | 1398 | 0.050 |
Why?
|
| Proteoglycans | 1 | 2001 | 47 | 0.050 |
Why?
|
| Laminin | 1 | 2001 | 61 | 0.050 |
Why?
|
| Drug Combinations | 1 | 2001 | 98 | 0.050 |
Why?
|
| DNA Primers | 1 | 2001 | 286 | 0.050 |
Why?
|
| Follow-Up Studies | 1 | 2023 | 974 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 110 | 0.050 |
Why?
|
| Latin America | 1 | 2020 | 45 | 0.050 |
Why?
|
| Cell Division | 1 | 2001 | 307 | 0.050 |
Why?
|
| Densitometry | 1 | 2010 | 13 | 0.050 |
Why?
|
| Collagen | 1 | 2001 | 172 | 0.050 |
Why?
|
| Mice, Nude | 1 | 2001 | 337 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2001 | 127 | 0.050 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 2010 | 98 | 0.050 |
Why?
|
| Limit of Detection | 1 | 2010 | 59 | 0.050 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2001 | 623 | 0.040 |
Why?
|
| Lung | 1 | 2003 | 446 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2002 | 356 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2020 | 104 | 0.040 |
Why?
|
| RNA | 1 | 2001 | 241 | 0.040 |
Why?
|
| Corneal Stroma | 1 | 1999 | 6 | 0.040 |
Why?
|
| Endothelium, Corneal | 1 | 1999 | 5 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2019 | 81 | 0.040 |
Why?
|
| Hospitalization | 1 | 2022 | 388 | 0.040 |
Why?
|
| Stromal Cells | 1 | 1999 | 49 | 0.040 |
Why?
|
| Asthma | 1 | 2003 | 380 | 0.040 |
Why?
|
| Odds Ratio | 1 | 2020 | 534 | 0.040 |
Why?
|
| Lipid Metabolism | 1 | 2019 | 119 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 623 | 0.040 |
Why?
|
| Prognosis | 1 | 2020 | 739 | 0.040 |
Why?
|
| Mice | 3 | 2003 | 5913 | 0.040 |
Why?
|
| Anti-Ulcer Agents | 1 | 2006 | 5 | 0.040 |
Why?
|
| Animals | 4 | 2003 | 15081 | 0.030 |
Why?
|
| Acids | 1 | 2006 | 18 | 0.030 |
Why?
|
| Cricetinae | 1 | 1996 | 238 | 0.030 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2006 | 71 | 0.030 |
Why?
|
| Multivariate Analysis | 1 | 2017 | 583 | 0.030 |
Why?
|
| Body Weight | 1 | 2017 | 434 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2019 | 485 | 0.030 |
Why?
|
| Smoking | 1 | 2019 | 940 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2016 | 1039 | 0.030 |
Why?
|
| Cell Movement | 1 | 2016 | 571 | 0.030 |
Why?
|
| Adolescent | 1 | 2023 | 5363 | 0.030 |
Why?
|
| Spectrophotometry, Infrared | 1 | 2012 | 37 | 0.030 |
Why?
|
| Indicators and Reagents | 1 | 2012 | 58 | 0.030 |
Why?
|
| Caspases | 2 | 2002 | 147 | 0.030 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2012 | 113 | 0.030 |
Why?
|
| Pyrazoles | 1 | 2012 | 85 | 0.020 |
Why?
|
| Caspase 3 | 2 | 2002 | 207 | 0.020 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2002 | 147 | 0.020 |
Why?
|
| Enzyme Activation | 2 | 2002 | 444 | 0.020 |
Why?
|
| Transfection | 2 | 2002 | 523 | 0.020 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2012 | 289 | 0.020 |
Why?
|
| Drug Design | 1 | 2012 | 162 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 2012 | 409 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2012 | 308 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 803 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4268 | 0.020 |
Why?
|
| Ophthalmoscopy | 1 | 2006 | 11 | 0.020 |
Why?
|
| Equipment Failure Analysis | 1 | 2006 | 41 | 0.020 |
Why?
|
| Equipment Design | 1 | 2006 | 124 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2006 | 562 | 0.020 |
Why?
|
| HIV Infections | 1 | 2017 | 2303 | 0.010 |
Why?
|
| Ovalbumin | 1 | 2003 | 47 | 0.010 |
Why?
|
| Oxidants | 1 | 2003 | 45 | 0.010 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2003 | 62 | 0.010 |
Why?
|
| Interleukin-8 | 1 | 2003 | 60 | 0.010 |
Why?
|
| Staurosporine | 1 | 2002 | 38 | 0.010 |
Why?
|
| Allergens | 1 | 2003 | 63 | 0.010 |
Why?
|
| Nucleosomes | 1 | 2002 | 29 | 0.010 |
Why?
|
| Benzamides | 1 | 2003 | 78 | 0.010 |
Why?
|
| Transcriptional Activation | 1 | 2003 | 172 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 2003 | 128 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2002 | 16 | 0.010 |
Why?
|
| Hydrogen Peroxide | 1 | 2003 | 190 | 0.010 |
Why?
|
| Deoxyribonucleases | 1 | 2002 | 25 | 0.010 |
Why?
|
| Mice, Mutant Strains | 1 | 2002 | 80 | 0.010 |
Why?
|
| NAD | 1 | 2002 | 50 | 0.010 |
Why?
|
| Protein Subunits | 1 | 2002 | 87 | 0.010 |
Why?
|
| Adenosine Triphosphate | 1 | 2002 | 196 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2002 | 515 | 0.010 |
Why?
|
| Enzyme Inhibitors | 1 | 2003 | 433 | 0.010 |
Why?
|
| NF-kappa B | 1 | 2003 | 339 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2003 | 933 | 0.010 |
Why?
|
| Calcium | 1 | 2002 | 480 | 0.010 |
Why?
|
| Inflammation | 1 | 2003 | 618 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2003 | 1609 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2002 | 1518 | 0.010 |
Why?
|